FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Reflections from our chief clinician: The essential role of our research... February 4, 2022 Reunión anual de la American Society of Clinical Oncology de 2022:... June 7, 2022 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Load more HOT NEWS News digest – skin cancer deaths, Public Health England plans and... EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... Qué debe saber sobre las pruebas de ADN en el hogar... New on NCI’s Websites for June 2022
